JBI-802 is under clinical development by Jubilant Therapeutics and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how JBI-802’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

JBI-802 overview

JBI-802 is under development for the treatment of melanoma, acute myeloid leukemia(AML), myelodysplastic syndrome, colon cancer, triple negative breast cancer (TNBC), small-cell lung cancer, myeloproliferative neoplasm, neuroendocrine tumors, solid tumor and neuro endocrine prostate cancer (NEPC). It is administered through oral route of administration. The therapeutic candidate acts by targeting both LSD1 and HDAC6.

Jubilant Therapeutics overview

Jubilant Therapeutics a subsidiary of Jubilant Life Sciences Ltd is a biopharmaceutical company that discovers, develops and commercializes gene-therapy medicines for the treatment of cancer, and autoimmune diseases. The company’s pipeline product candidates include LSD1/HDAC6 a novel dual epigenetic inhibitor for treating acute myeloid leukemia (AML); PAD4 inhibitors for the treatment rheumatoid arthritis, psoriasis; PRMT5 inhibitor targeting glioblastoma lymphoma; and PDL-1 small molecule for treating of multiple cancer. Jubilant Therapeutics collaborates with Frazier Healthcare Partners and Checkpoint Therapeutics Inc to develop novel therapies for the treatment of cancer. Jubilant Therapeutics is headquartered in Bedminster, New Jersey, the US.

For a complete picture of JBI-802’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.